THE ISSUE OF THIS PRESS RELEASE IS LIMITED TO CANADA ONLY. THIS PRESS RELEASE
SHOULD NOT BE ISSUED IN THE UNITED STATES THROUGH U.S. NEWS WIRE AGENCIES.


Osta Biotechnologies Inc. (TSX VENTURE:OBI) today announced that the journal
Cancer Research, a high impact publication of the American Association of Cancer
Research has published a paper in its October 15, 2009 issue containing the data
on Osta's novel anti-cancer therapeutic approach and has selected the paper to
appear as a highlight. The results summarized in this paper identify Heme
Oxygenase-1 (HO-1) as a potential biomarker and therapeutic target for hormone
refractory prostate cancer (HRPCA).


The article entitled "A novel experimental Heme Oxygenase-1 targeted therapy for
hormone-refractory prostate cancer" is accessible on online and can be found at
www.cancerres.aacrjournals.org.


The results contained in this publication demonstrate augmented HO-1 expression
in HRPCA tissue relative to hormone-responsive PCA and benign disease. HO-1 gene
silencing in HRPCA cells, or exposure of HRPCA cells to Osta's lead small
molecule inhibitor of HO-1, significantly reduced cell invasion in vitro and
tumor growth & metastasis formation in animal models. These results highlight
the clinical potential of targeting HO-1 in cancer.


Dr. Ajay Gupta, Chairman & CEO of Osta commented "The selection of this paper as
a highlight in this prestigious journal validates the solid science behind our
cancer therapeutic program directed towards the development of novel HO-1
inhibitors to treat advanced cancers."


The company also announced that it is currently focusing on the development of a
novel drug for cancer and Alzheimer's disease and has therefore, terminated a
license agreement with McGill University that covers the osteoporosis diagnostic
test technology. This diagnostic technology constitutes a non-core asset of the
company and is not of any interest to the company given its current research
focus on therapeutics development.


Osta Biotechnologies Inc.

Osta is a biopharmaceutical company listed on the TSX Venture Exchange (TSX
VENTURE:OBI) dedicated to developing novel diagnostics and therapeutics for the
aging population particularly in the areas of Cancer, Alzheimer's disease,
Osteoporosis, Osteoarthritis and XLH.


Certain information in this press release is forward-looking and is subject to
numerous risks and uncertainties. By their nature, such forward-looking
statements involve risks and uncertainties that could cause actual results to
differ materially from those contemplated by the forward-looking statements.
These risks include actions of Osta's competitors, and those inherent in
scientific research and development.
Osta Biotechnologies Inc. (TSXV:OBI)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Osta Biotechnologies Inc. Charts.
Osta Biotechnologies Inc. (TSXV:OBI)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Osta Biotechnologies Inc. Charts.